Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Colorcon
Mallinckrodt
Johnson and Johnson
Medtronic
Harvard Business School
Boehringer Ingelheim

Last Updated: October 15, 2019

DrugPatentWatch Database Preview

EPIDIOLEX Drug Profile

See Plans and Pricing

« Back to Dashboard

Which patents cover Epidiolex, and when can generic versions of Epidiolex launch?

Epidiolex is a drug marketed by Gw Res Ltd and is included in one NDA. There are nine patents protecting this drug.

This drug has fifty-one patent family members in fifteen countries.

The generic ingredient in EPIDIOLEX is cannabidiol. There are nine drug master file entries for this compound. Additional details are available on the cannabidiol profile page.

Drug patent expirations by year for EPIDIOLEX
Drug Prices for EPIDIOLEX

See drug prices for EPIDIOLEX

Generic Entry Opportunity Date for EPIDIOLEX
Generic Entry Date for EPIDIOLEX*:
Constraining patent/regulatory exclusivity:
INDICATED FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME (LGS) OR DRAVET SYNDROME (DS) IN PATIENTS 2 YEARS OF AGE AND OLDER
NDA:
Dosage:
SOLUTION;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for EPIDIOLEX

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Massachusetts General HospitalPhase 4
Medical University of South CarolinaPhase 1/Phase 2
GW Research LtdPhase 3

See all EPIDIOLEX clinical trials

Synonyms for EPIDIOLEX
(-)-Cannabidiol
(-)-Cannabidiol 1.0 mg/ml in Methanol
(-)-CBD
(-)-trans-2-p-Mentha-1,8-dien-3-yl-5-pentylresorcinol
(-)-trans-Cannabidiol
(1'R,2'R)-5'-methyl-4-pentyl-2'-(prop-1-en-2-yl)-1',2',3',4'-tetrahydrobiphenyl-2,6-diol
(3R,4R)-2-p-mentha-1,8-dien-3-yl-5-pentylresorcinol
1,3-Benzenediol, 2-(3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl)-5-pentyl-, (1R-trans)-
1,3-benzenediol, 2-[(1R,6R)-3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-
1,3-Benzenediol, 2-[3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-, (1R-trans)-
1,3-Benzenediol,2-[(1R,6R)-3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-
13956-29-1
18436-46-9
19GBJ60SN5
2-((1R,6R)-6-Isopropenyl-3-methyl-cyclohex-2-enyl)-5-pentyl-benzene-1,3-diol
2-(3-methyl-6-prop-1-en-2-yl-1-cyclohex-2-enyl)-5-pentyl-benzene-1,3-diol
2-(6-Isopropenyl-3-methyl-2-cyclohexen-1-yl)-5-pentyl-1,3-benzenediol #
2-(6-Isopropenyl-3-methyl-cyclohex-2-enyl)-5-pentyl-benzene-1,3-diol
2-(6-Isopropenyl-3-methyl-cyclohex-2-enyl)-5-pentyl-benzene-1,3-diol (Cannabidiol)
2-[(1R,6R)-3-methyl-6-prop-1-en-2-yl-1-cyclohex-2-enyl]-5-pentylbenzene-1,3-diol
2-[(1R,6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol
2-[3-Methyl-6-(methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol
20547-66-4
3556-78-3
4CN-1161
521-37-9
AC1LD8G2
AKOS032948358
BDBM50121429
BDBM50318484
C07578
cannabidiol
Cannabidiol (7CI)
Cannabidiol (USAN/INN)
Cannabidiol [USAN]
Cannabidiol solution
Cannabidiol solution, ~10 mg/mL in ethanol, analytical standard, for drug analysis
Cannabidiol solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material
Cannabidiol solution, 1.0 mg/mL in methanol, analytical standard, for drug analysis
cannabidiolum
CBD
CHEBI:69478
CHEMBL190461
D0O1UZ
D1(2)-trans-Cannabidiol
D10915
DB09061
Delta(1(2))-trans-cannabidiol
delta1(2)-trans-Cannabidiol
Epidiolex (TN)
GTPL4150
GWP42003-P
QHMBSVQNZZTUGM-ZWKOTPCHSA-N
Resorcinol, 2-p-mentha-1,8-dien-3-yl-5-pentyl-, (-)-(E)-
Resorcinol, 2-p-mentha-1,8-dien-3-yl-5-pentyl-, (+-)-
Resorcinol, 2-p-mentha-1,8-dien-3-yl-5-pentyl-, trans-(-)- (8CI)
SCHEMBL119679
UNII-19GBJ60SN5
UNII-K4H93P747O component QHMBSVQNZZTUGM-ZWKOTPCHSA-N
ZINC4097406
ZYN002

US Patents and Regulatory Information for EPIDIOLEX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Gw Res Ltd EPIDIOLEX cannabidiol SOLUTION;ORAL 210365-001 Sep 28, 2018 RX Yes Yes   See Pricing   See Pricing   See Pricing
Gw Res Ltd EPIDIOLEX cannabidiol SOLUTION;ORAL 210365-001 Sep 28, 2018 RX Yes Yes   See Pricing   See Pricing   See Pricing
Gw Res Ltd EPIDIOLEX cannabidiol SOLUTION;ORAL 210365-001 Sep 28, 2018 RX Yes Yes   See Pricing   See Pricing   See Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
McKinsey
Mallinckrodt
Johnson and Johnson
Merck
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.